Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. If successful, Elevidys label and geographic expansion is likely to unlock Sarepta's capacity to maintain a strong revenue growth pattern. Thus, supporting a “buy” rating for SRPT.

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Pfizer

Shares of Sarepta Therapeutics Inc. SRPT, -1.15% gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.

Pfizer's gene-therapy trial failure boosts Sarepta's stock

Casella Waste Systems

Datadog

If a portfolio is passively managed, investors tend to buy and forget. This however holds true for high-quality blue-chip and growth stocks.

Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate

Sarepta Therapeutics (NASDAQ:SRPT) is set to make a significant move by entering the S&P MidCap 400 index, replacing Shockwave Medical. This change, effective before trading begins on June 3, 2024, follows Johnson & Johnson's acquisition of Shockwave Medical.

Sarepta Therapeutics stock to enter S&P MidCap 400: Should you buy?

CRISPR Therapeutics

Vertex Pharmaceuticals

With the interest cuts coming up, it's an ideal time to consider loading up on the top biotech stocks. These stocks continue to dazzle with game-changing medical breakthroughs and explosive growth potential.

The 2030 Millionaire's Club: 3 Biotech Stocks to Buy Now

Regeneron Pharmaceuticals

Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions.

3 Biotech Stocks With the Potential to Make You an Overnight Millionaire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propell.

Gene Therapy Pioneer Jerry R. Mendell, M.D.

Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.97 per share a year ago.

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations & Corporate Communications Douglas Ingram - President & Chief Executive Officer Dallan Murray - Executive Vice President & Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer & Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Sarepta Therapeutics First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024. “We are pleased to announce another strong quarter of growth from our four approved therapies, posting net product revenue of $359.5 million, a 55% increase over the same quarter of the prior year, and achieving profitability on a GAAP and non-GAAP basis,” said Doug Ingram, president and chief execut.

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

Sarepta (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Sarepta (SRPT) Might Surprise This Earnings Season

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sare.

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

Sarepta Therapeutics reported strong Q4/2023 performance, with $365.1M in net product revenue, up 55% from the previous year. ELEVIDYS, despite not meeting its primary endpoint in the Phase III trial, showed significant improvements in motor function and secondary endpoints, keeping the potential for label expansion alive. SRPT's growth prospects, including potential label expansion for ELEVIDYS, have led to an updated strategy and bullish outlook for the company.

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Sarepta Therapeutics will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has already taken a beating.

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

Amgen

Amgen's lineup and pipeline should help its financial results and keep its dividend intact. While lesser known, Sarepta is proving itself to be a highly innovative biotech company.

2 Biotech Stocks to Buy Hand Over Fist in April

Cigna

Intuitive Surgical

Eli Lilly

PureCycle Technologies

Simplify Health Care ETF

The Simplify Health Care exchange-traded fund has grown to $136 million in assets in two and a half years. It is never easy for an actively managed fund to outperform its benchmark or a broad stock-market index, but Michael Taylor, the fund's lead manager, has done that so far.

Outperforming ETF manager names a potential ‘50-bagger' in the stock market

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Regenxbio reported some favorable data from a phase 1 clinical trial. Sarepta Therapeutics has a medicine on the market for the same target.

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

Enphase Energy

Alphabet

Biopharma company Sarepta Therapeutics is on the verge of reaching sustained profits. Last year was miserable for Enphase Energy, and this year isn't likely to be much better thanks to the tepid demand for residential solar solutions.

Got $1,000? Buy These Hot Growth Stocks Before They Take Off.

Sarepta Therapeutics is trying to widen its market for Elevidys. Regulators should deliver a verdict in early March.

Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences: Leerink Partners Global Biopharma Conference on Mon., March 11, 2024, at 10:00 a.m. E.T at the Fontainebleau Hotel in Miami, Fla. Barclays 26th Annual Global Healthcare Conference on Tue., March 12, 2024, at 3:05 p.m. E.T. at the Loews Miami Beach Ho.

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

News for Sarepta Therapeutics Stock (SRPT)